These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17884636)

  • 1. Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo.
    Wright AT; Cravatt BF
    Chem Biol; 2007 Sep; 14(9):1043-51. PubMed ID: 17884636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A suite of activity-based probes for human cytochrome P450 enzymes.
    Wright AT; Song JD; Cravatt BF
    J Am Chem Soc; 2009 Aug; 131(30):10692-700. PubMed ID: 19583257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Development of Novel Activity Probes for the Analysis of Human Cytochromes P450.
    Sellars JD; Skipsey M; Sadr-Ul-Shaheed ; Gravell S; Abumansour H; Kashtl G; Irfan J; Khot M; Pors K; Patterson LH; Sutton CW
    ChemMedChem; 2016 Jun; 11(11):1122-8. PubMed ID: 27154431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 networks in chemical space.
    Lee S; Kim D
    Arch Pharm Res; 2010 Sep; 33(9):1361-74. PubMed ID: 20945135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
    Murray M
    Clin Pharmacokinet; 1992 Aug; 23(2):132-46. PubMed ID: 1511529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors.
    Yap CW; Xue Y; Li ZR; Chen YZ
    Curr Top Med Chem; 2006; 6(15):1593-607. PubMed ID: 16918471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of chemical and antibody inhibitors for superior P450 3A inhibition in reaction phenotyping studies.
    Rock DA; Foti RS; Pearson JT
    Drug Metab Dispos; 2008 Dec; 36(12):2410-3. PubMed ID: 18765682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling Nonribosomal Peptide Synthetase Activities Using Chemical Proteomic Probes for Adenylation Domains.
    Ishikawa F; Konno S; Suzuki T; Dohmae N; Kakeya H
    ACS Chem Biol; 2015 Sep; 10(9):1989-97. PubMed ID: 26038981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.
    Tanaka E
    J Clin Pharm Ther; 1998 Dec; 23(6):403-16. PubMed ID: 10048501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.
    Weaver R; Graham KS; Beattie IG; Riley RJ
    Drug Metab Dispos; 2003 Jul; 31(7):955-66. PubMed ID: 12814974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A; Komorowski J; Wikberg JE
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic profiling of metalloprotease activities with cocktails of active-site probes.
    Sieber SA; Niessen S; Hoover HS; Cravatt BF
    Nat Chem Biol; 2006 May; 2(5):274-81. PubMed ID: 16565715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage.
    Zamora A; Denning CA; Heidary DK; Wachter E; Nease LA; Ruiz J; Glazer EC
    Dalton Trans; 2017 Feb; 46(7):2165-2173. PubMed ID: 28121322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems.
    McLean KJ; Dunford AJ; Neeli R; Driscoll MD; Munro AW
    Arch Biochem Biophys; 2007 Aug; 464(2):228-40. PubMed ID: 17482138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrochemical investigations of cytochrome P450.
    Shumyantseva VV; Bulko TV; Suprun EV; Chalenko YM; Vagin MY; Rudakov YO; Shatskaya MA; Archakov AI
    Biochim Biophys Acta; 2011 Jan; 1814(1):94-101. PubMed ID: 20650335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.
    Krausz KW; Goldfarb I; Buters JT; Yang TJ; Gonzalez FJ; Gelboin HV
    Drug Metab Dispos; 2001 Nov; 29(11):1410-23. PubMed ID: 11602516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies as a probe in cytochrome P450 research.
    Shou M; Lu AY
    Drug Metab Dispos; 2009 May; 37(5):925-31. PubMed ID: 19196844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
    Murray M
    Int J Mol Med; 1999 Mar; 3(3):227-38. PubMed ID: 10028046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photochromic agents as tools for protein structure study: lapachenole is a photoaffinity ligand of cytochrome P450 3A4.
    Gartner CA; Wen B; Wan J; Becker RS; Jones G; Gygi SP; Nelson SD
    Biochemistry; 2005 Feb; 44(6):1846-55. PubMed ID: 15697210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current methods of cytochrome p450 analysis].
    Moskaleva NE; Zgoda VG
    Biomed Khim; 2012; 58(6):617-34. PubMed ID: 23350195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.